search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
NEWS


AGC plans US plant expansion


AGC Chemicals Americas is to add 50% more manufacturing, QC lab and office space at its site at Thorndale in Pennsylvania, US. Construction has already commenced and completion is scheduled for July 2023. “The multi-use facility will be configured to meet the growing needs of current business and accommodate future production increases and new capabilities,” the company said. The Thorndale site is managed by the compa- ny’s Global Compounds business unit. AGC said it was chosen for expansion because of its strong technical capabilities in compounding fluoropoly- mer resins and its signifi- cant presence in the transportation, aerospace and energy markets. �www.agcchem.com


Avient ups medical focus


Avient Corporation’s production site at Taoyuan in Taiwan has secured ISO13485:2016 certification, giving the company a fourth global manufacturing location for its Mevopur medical compounds and enhancing its ability to service the China and Asia-Pacific healthcare sector. “China and other Asian countries not only have a rapidly growing domestic healthcare market, but they are also actively supporting Western countries for medical product manufac- turing, where they need to meet strict medical and pharma-related standards for testing, traceability, and change control of the materials used in their products. This is where the Mevopur product line, and local availability from Taiwan, become extremely important,” said Say-Eng Lee, Vice President and General Manager, Color & Additives Asia. The company already


Above: Avient is now manufacturing its Mevopur medical grades in Taiwan


produces Mevopur com- pounds at its ISO13485 compliant locations at Lewiston in Maine in the US, Malmö in Sweden, and in Singapore. Avient reported a 27%


growth in sales for 2021, reaching $4.8bn (adjusted to take account of the acquisition of the colour masterbatch activities of Clariant in July 2020). Full year adjusted EPS was up 58% to $3.05. “We delivered record results this year against a


backdrop of unprecedented challenges including the ongoing pandemic, sub- stantial raw material inflation, supply chain disruptions, and labour shortages,” said Chairman, President and CEO Robert M Patterson. While expecting material and labour shortages to continue into 2022, and for inflation to rise, the com- pany is forecasting a full year sales result of around $5.1bn. �www.avient.com


Vertellus acquires Polyscope Polymers


Vertellus has acquired Polyscope Polymers, the Netherlands-based manu- facturer of speciality additives for use in engi- neering polymers and other applications. The company said that the addition of a “comple- mentary product portfolio and advanced manufactur- ing capabilities” would expand its European production capabilities and extend its reach in to


www.compoundingworld.com


high-growth end markets. Polyscope, which is based


at Geleen, has sales and marketing opearations in


Europe, North America and Asia, and claims more than 300 customers in over 35 countries. It focuses on


production of styrene maleic anhydride (SMA), offering SMA and SMANPMI co and terpolymers and compounds for engineering plastic and speciality chemical applica- tions, which it markets globally under the Xiran and Xiloy brand names. �www.polyscope.euwww.vertellus.com


Left: Polyscope’s Xiran IZ terpolymers can enhance heat resistance


February 2022 | COMPOUNDING WORLD 5


IMAGE: POLYSCOPE


IMAGE: AVIENT/GETTY IMAGES


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66